A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)

Trial Profile

A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms PERSIST-5
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Feb 2017 Planned End Date changed from 1 May 2018 to 30 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top